The SVP & CFO of Codexis (CDXS) is Buying Shares


Today, the SVP & CFO of Codexis (CDXS), Gordon Sangster, bought shares of CDXS for $254.3K.

Following this transaction Gordon Sangster’s holding in the company was increased by 79.4% to a total of $2.28 million.

See today’s analyst top recommended stocks >>

Currently, Codexis has an average volume of 183.5K. The Company has a Price to Book ratio of 16.6808.

Starting in March 2018, CDXS received 13 Buy ratings in a row. Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $20.38, reflecting a 20.3% upside. Four different firms, including Cowen & Co. and Jefferies, currently also have a Buy rating on the stock.

The insider sentiment on Codexis has been negative according to 52 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Codexis, Inc. engages in the discovery, development, and sale of proteins. It offers enzyme optimization services and developing biocatalyst products. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts